Plus, news about Verastem Oncology, Oryzon Genomics, Azitra, Vivoryon Therapeutics and Akeso:
Merck cuts several Phase 2 programs: The company stopped work on two mid-stage programs testing experimental monoclonal antibodies in combination with Keytruda: quavonlimab ...
↧